CA2331333A1 - Antisense oligonucleotide constructs based on .beta.-arabinofuranose and its analogues - Google Patents

Antisense oligonucleotide constructs based on .beta.-arabinofuranose and its analogues Download PDF

Info

Publication number
CA2331333A1
CA2331333A1 CA002331333A CA2331333A CA2331333A1 CA 2331333 A1 CA2331333 A1 CA 2331333A1 CA 002331333 A CA002331333 A CA 002331333A CA 2331333 A CA2331333 A CA 2331333A CA 2331333 A1 CA2331333 A1 CA 2331333A1
Authority
CA
Canada
Prior art keywords
relates
arabinofuranose
analogues
beta
antisense oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002331333A
Other languages
French (fr)
Other versions
CA2331333C (en
Inventor
Massad Jose Damha
Michael A. Parniak
Anne M. Noronha
Christopher Wilds
Gadip Borkow
Dominique Arion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Original Assignee
Mcgill University
Massad Jose Damha
Michael A. Parniak
Anne M. Noronha
Christopher Wilds
Gadip Borkow
Dominique Arion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcgill University, Massad Jose Damha, Michael A. Parniak, Anne M. Noronha, Christopher Wilds, Gadip Borkow, Dominique Arion filed Critical Mcgill University
Priority to CA002331333A priority Critical patent/CA2331333C/en
Priority to CA002618288A priority patent/CA2618288A1/en
Priority claimed from PCT/CA1999/000571 external-priority patent/WO1999067378A1/en
Publication of CA2331333A1 publication Critical patent/CA2331333A1/en
Application granted granted Critical
Publication of CA2331333C publication Critical patent/CA2331333C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Abstract

The present invention relates to modified oligonucleotide therapeutic agents to selectively prevent gene transcription and expression in a sequence-specific manner. In particular, this invention relates to the selective inhibition of protein biosynthesis via antisense strategy using oligonucleotides constructed from arabinonucleotide or modified arabinonucleotide residues. More particularly this invention relates to the use of antisense oligonucleotides having arabinose sugars to hybridize to complementary RNA such as cellular messenger RNA, viral RNA, etc.
CA002331333A 1998-06-19 1999-06-17 Antisense oligonucleotide constructs based on .beta.-arabinofuranose and its analogues Expired - Fee Related CA2331333C (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002331333A CA2331333C (en) 1998-06-19 1999-06-17 Antisense oligonucleotide constructs based on .beta.-arabinofuranose and its analogues
CA002618288A CA2618288A1 (en) 1998-06-19 1999-06-17 Antisense oligonucleotide constructs based on .beta.-arabinofuranose and its analogues

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA2241361 1998-06-19
CA2,241,361 1998-06-19
PCT/CA1999/000571 WO1999067378A1 (en) 1998-06-19 1999-06-17 ANTISENSE OLIGONUCLEOTIDE CONSTRUCTS BASED ON β-ARABINOFURANOSE AND ITS ANALOGUES
CA002331333A CA2331333C (en) 1998-06-19 1999-06-17 Antisense oligonucleotide constructs based on .beta.-arabinofuranose and its analogues

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002618288A Division CA2618288A1 (en) 1998-06-19 1999-06-17 Antisense oligonucleotide constructs based on .beta.-arabinofuranose and its analogues

Publications (2)

Publication Number Publication Date
CA2331333A1 true CA2331333A1 (en) 1999-12-29
CA2331333C CA2331333C (en) 2008-05-20

Family

ID=25680318

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002618288A Abandoned CA2618288A1 (en) 1998-06-19 1999-06-17 Antisense oligonucleotide constructs based on .beta.-arabinofuranose and its analogues
CA002331333A Expired - Fee Related CA2331333C (en) 1998-06-19 1999-06-17 Antisense oligonucleotide constructs based on .beta.-arabinofuranose and its analogues

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002618288A Abandoned CA2618288A1 (en) 1998-06-19 1999-06-17 Antisense oligonucleotide constructs based on .beta.-arabinofuranose and its analogues

Country Status (1)

Country Link
CA (2) CA2618288A1 (en)

Also Published As

Publication number Publication date
CA2331333C (en) 2008-05-20
CA2618288A1 (en) 1999-12-29

Similar Documents

Publication Publication Date Title
AU4595399A (en) Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues
WO2003100017A3 (en) Oligonucleotides having modified nucleoside units
WO2002026967A3 (en) Targeted gene correction by single-stranded oligodeoxynucleotides
EP2752488A3 (en) Antisense design
AU5121399A (en) Rna targeted 2'-modified oligonucleotides that are conformationally preorganized
WO2001092512A3 (en) Targeted chromosomal genomic alterations in plants using modified single stranded oligonucleotides
ZA200304500B (en) Method for inhibiting the expression of a target gene and medicament for treating a tumor disease.
WO2001047944A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
EP1544297A3 (en) Medicament for treatment of Duchenne muscular dystrophy
EP0961837A4 (en) Three component chimeric antisense oligonucleotides
WO1998005769A3 (en) Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
AU6589094A (en) 7-deazapurine modified oligonucleotides
WO2007031319A8 (en) Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides
EP1485401A4 (en) Trpm-2 antisense therapy using an oligonucleotide having 2'-o-(-2-methoxyl)ethyl modifications
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
WO2006102970A3 (en) Modified short interfering rna
WO2002020773A3 (en) Chimeric antisense oligonucleotides of arabinofuranose analogues and deoxyribose nucleotides
WO2000029623A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
AU3295700A (en) Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same
CA2495298A1 (en) Use of antisense oligonucleotides to inhibit the expression of akt-1
WO2000008140A3 (en) Antisense oligonucleotides for the inhibition of vegf expression
CA2331333A1 (en) Antisense oligonucleotide constructs based on .beta.-arabinofuranose and its analogues
WO2001048245A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2001040521A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
AU7733200A (en) Compositions and methods for reducing oligonucleotide hybridization and priming specificity

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed